Carlsmed, Inc. (CARL) vs Kyverna Therapeutics, Inc. (KYTX)
A side-by-side comparison of Carlsmed, Inc. and Kyverna Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CARL
Carlsmed, Inc.
$14.89HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT
KYTX
Kyverna Therapeutics, Inc.
$6.25HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT
Total return — CARL vs KYTX
growth of $100 · dividends reinvested · last 1yCARL +5.5% (+5.5%/yr)KYTX +46.0% (+46.0%/yr)KYTX compounded faster over this window
CARL KYTX
CARL vs KYTX: by the numbers
- •CARL is the larger company ($405M vs $380M market cap).
- •Both run net losses; KYTX's is the smaller (0.00% vs -57.42% net margin).
Metrics side by side
Valuation
| Metric | CARL | KYTX |
|---|---|---|
| P/S ratio | 6.40 | N/A |
| P/B ratio | 4.80 | 2.30 |
Profitability
| Metric | CARL | KYTX |
|---|---|---|
| Gross margin | 76.63% | 0.00% |
| Operating margin | -61.09% | 0.00% |
| Net margin | -57.42% | 0.00% |
| ROE | -43.14% | -92.20% |
| ROIC | -36.54% | -80.67% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.